Comparative Pharmacology
Head-to-head clinical analysis: GANTRISIN versus SULFONAMIDES DUPLEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GANTRISIN versus SULFONAMIDES DUPLEX.
GANTRISIN vs SULFONAMIDES DUPLEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of dihydropteroate synthase, blocking para-aminobenzoic acid (PABA) incorporation into dihydropteroic acid, thereby inhibiting bacterial folate synthesis and nucleic acid production.
Sulfonamides are competitive antagonists of para-aminobenzoic acid (PABA) and inhibit dihydropteroate synthase, blocking folate synthesis in susceptible bacteria.
2-4 g orally initially, then 4-8 g daily in 3-6 divided doses
Oral: 500-1000 mg twice daily; maximum 2000 mg/day.
None Documented
None Documented
7-12 hours (mean 10 hours); prolonged to 20-50 hours in renal impairment (CrCl <30 mL/min)
Terminal half-life: 7-12 hours in patients with normal renal function; prolonged to 24-50 hours in renal impairment (CrCl <30 mL/min) due to reduced elimination.
Renal: 70% as unchanged drug; hepatic metabolism: 30% as acetylated metabolites; biliary: <3%
Renal: 70-100% unchanged drug via glomerular filtration and tubular secretion; fecal/biliary: <5%.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic